Management of Ulcerative Colitis After Azathioprine Failure

Introduction to Biologic Therapy

The American Gastroenterological Association recommends advancing directly to biologic therapy, specifically infliximab combined with continuation of azathioprine, or vedolizumab monotherapy if combination therapy is not feasible, after azathioprine failure in ulcerative colitis patients 1, 2

Infliximab is the preferred first biologic after azathioprine failure, ideally continued in combination with azathioprine, with a corticosteroid-free remission rate of 39.7% at 16 weeks, according to the European Crohn’s and Colitis Organisation 3, 4
Vedolizumab is an equally appropriate first-line option, particularly for patients who cannot tolerate combination therapy, with lower rates of infectious complications than TNF antagonists, as suggested by the American Gastroenterological Association 1, 2

Golimumab can be used as first-line therapy, preferably with continued azathioprine, according to the European Crohn’s and Colitis Organisation 1, 3
Ustekinumab is appropriate for biologic-naïve patients after thiopurine failure, as recommended by the American Gastroenterological Association 1

The American Gastroenterological Association advises against using adalimumab as first-line biologic therapy after azathioprine failure due to its inferior efficacy compared to infliximab and vedolizumab in biologic-naïve patients 2
The European Crohn’s and Colitis Organisation recommends against discontinuing azathioprine when starting infliximab, unless there are specific safety concerns or intolerance, as the combination is significantly more effective than either agent alone 3, 4
The American Gastroenterological Association suggests not using methotrexate monotherapy, as it is not recommended for either induction or maintenance of remission in ulcerative colitis 1, 5
The American Gastroenterological Association advises against continuing 5-aminosalicylates once biologic therapy is initiated, as they provide no additional benefit for maintaining remission in moderate-to-severe disease 1, 6, 7

The European Crohn’s and Colitis Organisation recommends switching to an alternative anti-TNF agent, such as switching to an alternative anti-TNF agent if infliximab was used first, or switching to vedolizumab, particularly effective after anti-TNF failure, with 36.1% achieving remission at 52 weeks 3, 4, 5
The American Gastroenterological Association suggests using higher efficacy medications, including tofacitinib, upadacitinib, or ustekinumab, over intermediate efficacy options after one biologic failure 1

The European Crohn’s and Colitis Organisation states that the benefit of combination therapy is most clearly established for infliximab, with a significant increase in efficacy when combined with azathioprine 3, 4, 1
The American Gastroenterological Association notes that for non-TNF biologics, such as vedolizumab and ustekinumab, there is insufficient evidence to recommend for or against combination therapy with immunomodulators 1

The American Gastroenterological Association recommends proceeding with biologic monotherapy using infliximab, vedolizumab, or ustekinumab if azathioprine must be stopped due to intolerance or adverse effects 1, 2
The American Gastroenterological Association advises against substituting methotrexate as an alternative immunomodulator for maintenance therapy in ulcerative colitis 1, 5

The American Gastroenterological Association suggests using intravenous cyclosporine or infliximab as rescue therapy for hospitalized patients with acute severe ulcerative colitis refractory to intravenous corticosteroids after azathioprine failure 2

The European Crohn’s and Colitis Organisation recommends discussing surgery as an option when advancing through multiple therapeutic agents, as there is generally a reduction in response to each successive immunosuppressive or biologic drug 5
The European Crohn’s and Colitis Organisation notes that up to 10% of patients requiring colectomy have only distal colitis, and outcomes of colectomy with pouch formation are generally good 4, 3